Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Xypex 2025 International Best Project Awards - Winners Announced19.3.2026 21:00:00 CET | Press release
Xypex announces 2025 award winners recognizing excellence in concrete durability, engineering performance, and crystalline waterproofing technology. VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / Xypex announces the winners of the 2025 International Best Project Awards, recognizing construction projects that demonstrate excellence in concrete durability, engineering performance, and the use of crystalline waterproofing technology. This year's program received more than 80 project submissions from over 20 countries across five continents, reflecting the global reach of Xypex technology and the strength of its international network of distributors, engineers, contractors, and partners. The submissions represented a broad range of projects across infrastructure, general construction, water and wastewater facilities, industrial structures, and small-scale applications. Projects were evaluated based on engineering complexity, construction challenges, durability requirements, and the int
Brookville DMAX Expansion Highlights the Project Work Behind a Major Ohio Manufacturing Investment19.3.2026 16:00:00 CET | Press release
BROOKVILLE, OH / ACCESS Newswire / March 19, 2026 / General Motors' Duramax Engine Plant (DMAX) expansion in Brookville has become one of the region's most significant industrial projects, tied to a $920 million investment supporting Duramax diesel engine production for GM heavy-duty truck programs, including Chevrolet Silverado HD and GMC Sierra HD models. Public reporting has described the Brookville work as adding about 1.1 million square feet to the existing facility which was previously approximately 250,000 square feet. Notably, the project has created and supported hundreds of local jobs as the site expands its manufacturing footprint in southwest Ohio. This expansion quadruples the current facility size and is designed to create over 800 jobs, supporting high demand for diesel trucks. Among the professionals helping carry that work forward is Sabra Sadeghi, a project architect and engineer who served on the Brookville expansion in an on-site role. The project has been praised f
U.S. Polo Assn. Unveils 2026 Spring-Summer Global Collection, Inspired by Coastal Charleston, South Carolina19.3.2026 12:00:00 CET | Press release
Seasonal and Seaside Styles Debut Alongside U.S. Open Polo Championship Capsule WEST PALM BEACH, FL / ACCESS Newswire / March 19, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has launched its sport-inspired Spring-Summer 2026 Global Collection, a vibrant seasonal lineup inspired by coastal Americana and the relaxed spirit of seaside living. The campaign was photographed in historic Charleston, South Carolina, where Rainbow Row's pastel architecture, coastal landscapes, and the heritage of the Hyde Park Polo Club field create the perfect backdrop for the iconic global brand's latest styles.U.S. Polo Assn. 2026 Spring-Summer Global Collection Photoshoot in Charleston, South Carolina The U.S. Polo Assn. campaign once again highlights the authentic connection between the sport of polo and the globally recognized lifestyle brand inspired by the sport. Apparel and accessories from the Spring-Summer 2026 Global Collection are now available. G
Datavault AI Enters into Definitive Agreement to Acquire NYIAX, Combining AI-Driven Data Monetization with Institutional-Grade Market Infrastructure19.3.2026 11:30:00 CET | Press release
Pending acquisition will integrate NYIAX's blockchain-enabled exchange platform, built on globally recognized financial market technology and jointly owned patents to power next-generation digital marketplaces. PHILADELPHIA, PA / ACCESS Newswire / March 19, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the signing of a Definitive Agreement to acquire NYIAX Inc. ("NYIAX"). The acquisition will bring NYIAX's intellectual property portfolio and blockchain-powered trading platform built on a globally recognized financial market infrastructure platform into Datavault AI's organization. The combined company is expected to make institutional-grade, transparent trading infrastructure available to customers and accelerate the planned commercial launches of specialized exchanges. The transaction builds upon an October 2025 letter of inte
Powerverse and Teltonika Energy Partner to Unlock Intelligent Home Energy & Flexibility19.3.2026 08:00:00 CET | Press release
LONDON, UK / ACCESS Newswire / March 19, 2026 / Powerverse has partnered with Teltonika Energy, part of the Teltonika group, a multinational leader in IoT innovation, to deliver an AI-driven home energy ecosystem that enhances user experience, unlocks flexibility services and drives long-term customer value. Teltonika Energy's hardware is built with reliability, connectivity and performance at its core, and its devices are designed to support the next generation of intelligent home energy systems. "Teltonika Energy is globally recognised for its high-quality, IoT-engineered hardware," said Richard Britton, CEO of Powerverse. "We are thrilled to combine their robust devices with our AI-driven platform to help customers move beyond simple smart control and into active market participation. Together, we are delivering a fully integrated, end-to-end solution that makes it effortless for users to lower costs, reduce their carbon footprint, and unlock the full long-term value of home energy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom